Biological Testing Facility (X01 Clinical Trial Not Allowed)
ID: 346940Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346940

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-128.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at advancing contraceptive development programs. This grant provides a mechanism for investigators to request services from the facility, focusing on innovative and validated methods for future clinical development, without requiring current NIH funding for application. Eligible applicants include a diverse range of organizations, such as Historically Black Colleges and Universities, Tribal Governments, and foreign entities, among others. The application deadline is May 2, 2025, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-128.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-128-Full-Announcement.html
    Similar Opportunities
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at supporting research in the development of non-hormonal contraceptive methods. This grant allows investigators to access the Biological Testing Facility (BTF) for preclinical studies and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies, with a focus on advancing contraceptive development to address unintended pregnancies in the U.S. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications due by May 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-192.html.
    Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is offering a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to support the development of non-hormonal contraceptives and reproductive health products by providing access to a state-of-the-art facility that offers preclinical services, including protein generation, high throughput screening, and drug metabolism studies. The program is designed to facilitate research that leads to safe and effective reproductive health therapies, with a focus on innovation and scientific merit in project proposals. Applications are open from September 3, 2023, with deadlines on October 3 and April 3 annually until 2026. Eligible applicants include various organizations such as higher education institutions, non-profits, and tribal governments. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Contraceptive Development Research Centers (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Contraceptive Development Research Centers (P50 Clinical Trial Optional)" aimed at advancing the development of new and improved contraceptive methods for both men and women. This initiative seeks to establish multidisciplinary Contraceptive Development Research Centers that will conduct laboratory and clinical research, including translational studies to enhance the likelihood of clinical success. The program is particularly focused on late-stage preclinical or clinical development of contraceptive products, encouraging proposals that explore innovative options such as non-steroidal contraceptives and novel delivery mechanisms. Up to $6 million in funding is available for fiscal year 2026, with a project period of up to four years. Interested applicants must submit their proposals by November 13, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting projects that develop innovative technologies to enhance biomedical research capabilities. Eligible applicants include a diverse range of institutions such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that have demonstrated proof of principle but still face significant technical challenges. This initiative emphasizes the development of laboratory instruments, algorithms, and biological systems, while applications targeting specific biomedical questions will not be funded. Interested parties should note that the application deadline is May 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-127.html.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.